Topical sphingosine 1 phosphate receptor agonist active agent formulations are provided. Aspects of the transdermal formulations include an amount of a sphingosine 1 phosphate receptor agonist active agent in combination with a topical delivery vehicle e.g. a topical patch that includes an adhesive layer and a backing layer. Also provided are methods of topically delivering a therapeutically effective amount of a sphingosine 1 phosphate receptor agonist active agent to a subject e.g. to treat a subject for a disease condition such as an immune system disorder like multiple sclerosis a hyperproliferative dermatological disorder e.g. psoriasis acne etc. Packaged topical formulations kits including such formulations and methods of making such formulations are also provided.
